Turski Christopher A, Jacobs Mitchell A, Abou-Jaoude Michelle M, Fowler Nicholas H, Harpole Ryan, Altman Emily, Chadwell John B, Kindl Gabriel, James Hayley R, Reddy Shivani V, Maldonado Ramiro S
Department of Ophthalmology, University of Kentucky, Lexington, KY, USA.
Department of Ophthalmology, Duke University Eye Center, 2351 Erwin Rd, Durham, NC, 27710, USA.
Int J Retina Vitreous. 2022 Nov 17;8(1):81. doi: 10.1186/s40942-022-00430-z.
A significant portion of diabetic macular edema (DME) is refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. This study investigates morphological and functional outcomes to a single intravitreal bevacizumab (IVB) injection in patients with center-involving DME (ciDME) at 4-6 weeks and compares treatment responders and non-responders based on spectral domain optical coherence tomography (SD-OCT) features.
IRB approved observational, retrospective chart review of patients with ciDME, identified by ICD-10 code, who received IVB and underwent baseline and 4-6 weeks follow-up SD-OCT imaging between January 1, 2016 and January 19, 2021. Patients who had received previous treatment with anti-VEGF or intraocular steroids within 1 year were excluded. Variables included best-corrected visual acuity (BCVA), central subfield thickness (CST) and total macular volume (TMV). Eyes were classified as responders if CST reduction was greater than 10%. OCT scans were graded qualitatively by two masked graders using Imagivault software. Paired Student's t-tests, Wilcoxon signed rank tests and Chi-Square tests were used for analysis.
A total of 334 prospective subjects were identified, and after applying exclusion criteria 52 eyes from 46 patients (mean age 64.22 ± 8.12 years, 58.7% male) were included. Mean BCVA did not significantly change with treatment, 63.9 ETDRS letters (~ 20/50) at baseline and 65.9 ETDRS letters (~ 20/50) post-treatment (p = 0.07). Mean CST decreased from 466 ± 123 μm at baseline to 402 ± 86 μm post-treatment (p < 0.001). 22 (42.3%) of eyes were categorized as responders and 30 (57.7%) as non-responders. Average change in CST from baseline in responders was -164 μm (p < 0.001) and + 9 μm in non-responders (p = 0.47). Vitreomacular adhesion (VMA) was more prevalent in non-responders (28.7% vs. 4.8%, p = 0.03). In addition, cyst location in the inner nuclear layer (INL) was present more frequently in responders (95.5% vs. 73.3%, p = 0.037) as was subretinal fluid (45.5% vs. 13.3%, p = 0.01).
The short-term response to a single IVB was sub-optimal with structural but no functional improvements. Greater baseline CST, presence of INL cysts and subretinal fluid may represent factors indicative of a better treatment response.
相当一部分糖尿病性黄斑水肿(DME)患者对抗血管内皮生长因子(anti-VEGF)药物治疗无效。本研究调查了累及黄斑中心凹的DME(ciDME)患者单次玻璃体内注射贝伐单抗(IVB)后4至6周的形态学和功能学结果,并根据频域光学相干断层扫描(SD-OCT)特征比较了治疗反应者和无反应者。
通过IRB批准的对ciDME患者的观察性、回顾性病历审查,这些患者通过ICD-10编码识别,于2016年1月1日至2021年1月19日期间接受了IVB治疗,并进行了基线和4至6周随访的SD-OCT成像。排除在1年内接受过抗VEGF或眼内类固醇治疗的患者。变量包括最佳矫正视力(BCVA)、中心子野厚度(CST)和黄斑总体积(TMV)。如果CST降低大于10%,则将眼部分类为反应者。两名盲态评分者使用Imagivault软件对OCT扫描进行定性评分。采用配对t检验、Wilcoxon符号秩检验和卡方检验进行分析。
共识别出334名前瞻性受试者,应用排除标准后,纳入了46例患者的52只眼(平均年龄64.22±8.12岁,男性占58.7%)。治疗后平均BCVA无显著变化,基线时为63.9 ETDRS字母(约20/5)治疗后为65.9 ETDRS字母(约20/50)(p=0.07)。平均CST从基线时的466±123μm降至治疗后的402±86μm(p<0.001)。22只眼(42.3%)被分类为反应者,30只眼(57.7%)为无反应者。反应者CST相对于基线的平均变化为-164μm(p<0.001),无反应者为+9μm(p=0.47)。玻璃体黄斑粘连(VMA)在无反应者中更常见(28.7%对4.8%,p=0.03)。此外,反应者中内核层(INL)的囊肿位置更常见(95.5%对73.3%,p=0.037),视网膜下液也是如此(45.5%对13.3%,p=0.01)。
单次IVB的短期反应不理想,虽有结构改善但无功能改善。更高的基线CST、INL囊肿的存在和视网膜下液可能代表了更好治疗反应的指示因素。